ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B-Lymphocyte"

  • Abstract Number: 0001 • ACR Convergence 2024

    Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus

    Diana Alzamareh1, Nida Pellett2, Daria Krenitsky2, Wesley Durrett1, Javier Rangel-Moreno1, Jennifer Anolik2 and Jennifer Barnas1, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of pathogenic anti-nuclear antibodies (ANA) by plasma cells (PC).  Importantly, long-lived plasma…
  • Abstract Number: 0839 • ACR Convergence 2024

    Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity

    Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
  • Abstract Number: 1784 • ACR Convergence 2024

    T-bet Expressing B Cells as a Putative Prognostic and Therapeutic Biomarker for Human SLE

    Athanasios Sachinidis1, Maria Trachana2, Anna Taparkou2, George Gavriilidis3, Vasileios Vasileiou3, Sofoklis Keisaris3, Panayotis Verginis4, Christina Adamichou5, Dimitrios Boumpas6 and Alexandros Garyfallos2, 1School of Medicine, Aristotle University of Thessaloniki, Greece, Thessaloniki, Greece, 2Ippokrateio General Hospital Thessaloniki, Thessaloniki, Greece, 3Centre for Research and Technology Hellas, Thessaloniki, Greece, 4Medical School, University of Crete, Heraklion, Crete, Greece, 5IPPOKRATEION HOSPITAL OF THESSALONIKI, Athens, Greece, 64th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece

    Background/Purpose: T-bet+ B cells, known as age-associated B cells (ABCs) and/or double-negative B cells (DN), expand in various autoimmune diseases. This study aimed to clarify…
  • Abstract Number: 0007 • ACR Convergence 2024

    Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation

    Ryota Sato1, Mitsuhiro Akiyama2, Koichi Oshita3, Yuko Kawano3, Yuki Imura3, Piruzyan Mariam4, Manami Kikuchi3, Mikako Murase3, Sachiko Mochiduki3, Naohiro Hashimoto3, Masayuki Watanabe3, Keiko Yoshimoto5, Tsutomu Takeuchi6, Kenji Chiba7 and Yuko Kaneko5, 1Mitsubishi Tanabe Pharma Corporation, Brighton, MA, 2Keio University School of Medicine, Palo Alto, CA, 3Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 4Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, 5Keio University School of Medicine, Tokyo, Japan, 6Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 7Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan

    Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
  • Abstract Number: 0897 • ACR Convergence 2024

    Dynamic eQTLs from Activated Human B Cells Suggest Cell-state Dependent Effects for GWAS Risk Variants in BLK

    Yao Fu, David Murphy, Richard Pelikan, Jeniffer Kelly, Kiely Grundahl, Satish Pasula, Kandice Tessneer and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic disease in which B cells play a critical role in pathogenesis. Previous genome-wide association studies (GWAS)…
  • Abstract Number: 1786 • ACR Convergence 2024

    Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine

    Christian Wright1, Rufei Lu2, Catriona Wagner3, Carla Guthridge4, Susan Macwana1, Eliza Chakravarty4, Tammy Utset5, Diane Kamen6, Gabriel Nicolas Contreras Martin7, William McCune8, Cynthia Aranow9, Kenneth Kalunian10, Elena Massarotti11, Megan Clowse12, Brad Rovin13, S. Sam Lim14, Vikas Majithia15, Richard Looney16, Maria Dall'Era17, Doruk Erkan18, Amit Saxena19, Nancy Olsen20, Kichul Ko21, Ellen Goldmuntz22, William Barry23, Ashley Pinckney24, ALE06 Clinical Study Team4, Judith James4 and Joel Guthridge4, 1Oklahoma Medical Research Foundation, Oklahoma City, 2University of California San Francisco, San Bruno, CA, 3Oklahoma Medical Research Foundation, Santa Cruz, CA, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5University of Chicago, Chicago, IL, 6Medical University of South Carolina, Charleston, SC, 7University of Miami, Key Biscayne, FL, 8U Michigan, Ann Arbor, MI, 9Feinstein Institutes for Medical Research, New York, NY, 10University of California San Diego, La Jolla, CA, 11Brigham and Women's Hospital, Boston, MA, 12Duke University, Chapel Hill, NC, 13The Ohio State University, Columbus, OH, 14Emory University, Atlanta, GA, 15Mayo Clinic Florida, Jacksonville, FL, 16University of Rochester, Rochester, NY, 17UCSF, Corte Madera, CA, 18Hospital for Special Surgery, New York, NY, 19NYU School of Medicine, New York, NY, 20Penn State University/Milton S Hershey, Hershey, PA, 21The University of Chicago, Chicago, IL, 22NIAID/ NIH, Washington, DC, 23Rho, Inc, Durham, NC, 24Rho, St Louis Park, NC

    Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
  • Abstract Number: 0012 • ACR Convergence 2024

    Dichotomous Expression of CXCR3 and CCR9 and Relationship to Intestinal Permeability in B Cells in Rheumatoid Arthritis

    Ken Yasaka, Ruoqiao Wang, Nida Pellett, Daria Krenitsky, Juilee Thakar and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: The gut is a key mucosal tissue that can impact the immune system and contribute to systemic inflammation in the setting of increased intestinal…
  • Abstract Number: 0905 • ACR Convergence 2024

    High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes

    Rufei Lu1, Andrea Fava2, Benjamin Jones3, Peter Izmirly4, Jennifer Anolik5, Chaim Putterman6, David Wofsy7, Matthias Kretzler8, Celine Berthier9, E. Steve Woodle10, Michael Weisman11, Mariko Ishimori12, The Accelerating medicines Partnership: RA/SLE Network13, Betty Diamond14, Jill Buyon15, Michelle Petri16, Richard Furie17, Judith James13 and Joel Guthridge13, 1University of California San Francisco, San Bruno, CA, 2Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 3Oklahoma State University, Oklahoma City, OK, 4New York University Grossman School of Medicine, New York, NY, 5University of Rochester Medical Center, Rochester, NY, 6Albert Einstein College of Medicine, Safed, Israel, 7University of California San Francisco, SF, CA, 8University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, 9University of Michigan, Ann Arbor, MI, 10University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, 11Stanford University, Los Angeles, CA, 12Cedars-Sinai Health System, Los Angeles, CA, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14The Feinstein Institutes for Medical Research, Manhasset, NY, 15NYU Grossman School of Medicine, New York, NY, 16Johns Hopkins University School of Medicine, Timonium, MD, 17Northwell Health, Manhasset, NY

    Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
  • Abstract Number: 1804 • ACR Convergence 2024

    Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…
  • Abstract Number: 0015 • ACR Convergence 2024

    Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution

    Ana Merino Vico1, Yosta Vegting1, Aldo Jongejan1, Jan Piet van Hamburg1, Perry moerland1, Sander Tas2 and Marc Hilhorst1, 1Amsterdam UMC, Amsterdam, Netherlands, 2Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
  • Abstract Number: 0911 • ACR Convergence 2024

    Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants

    David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
  • Abstract Number: 1807 • ACR Convergence 2024

    Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus

    Takehiro Hirayama1, Hyota Takamatsu2 and Atsushi Kumanogoh3, 1Osaka university, ibaraki city, Japan, 2National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, 3Osaka University, Osaka, Japan

    Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
  • Abstract Number: 0016 • ACR Convergence 2024

    Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology

    Lichchavi Rajasinghe1, Govinda Rocky Thomas,2, Jee Ho Lee1, Gary Sims1 and Tatiana Ort1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2AstraZeneca Pharmaceuticals, Gaithersburg, MD

    Background/Purpose: Germinal centers (GC) are specialized lymphoid structures found within the B cell follicles of secondary lymphoid tissue formed following infection or immunization. They are…
  • Abstract Number: 1139 • ACR Convergence 2024

    Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes

    Shinji Izuka1, Toshihiko Komai2, Hayato Yuuki2, Ikuko Ueda3, Manabu Fujimoto4, Hiroyuki Fukui5, Masaru Takeshita6, Natsuka Umezawa7, Shinsuke Yasuda7, Mitsutaka Yasuda8, Yuichiro Fujieda9, Tatsuya Atsumi9, Takeshi Iwasaki10, Akio Morinobu10, Yuya Kondo11, Isao Matsumoto11, Toshio Kawamoto12, Masakazu Matsushita12, Naoto Tamura13, Taro Iwamoto14, Hiroshi Nakajima14, Ken Yoshida15, Takeo Isozaki16, Nobuyuki Yajima16, Keiichi Sakurai17, Kimito Kawahata17, Yasuyuki Kamata18, Kojiro Sato18, Yoshiya Tanaka19, Akari Suzuki20, Kazuhiko Yamamoto21, Tomohisa Okamura22 and Keishi Fujio2, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, 3Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, 4Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, 6Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 7Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, 9Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 10Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, 11Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, 12Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, 13Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 14Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, 15Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, 16Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, 17Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, 18Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, 19Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 20Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, 21Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, 22Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
  • Abstract Number: 1842 • ACR Convergence 2024

    Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy

    John Goulding1, John Reiser2, Alison O'Connor1, Bryan Hancock1, Jonatan Tuncel1, Brian Groff1, Rina Mbofung1, Daniel Morales-Mantilla1, Allan Williams1, Dan Lu1, Bi-Huei Yang1, Eigen Peralta1, Alma Gutierrez1, Miguel Meza1, Betsy Rezner1, Amanda Sims1, Alec Witty1, Yijia Pan1, Mark Jelcic1, Shohreh Sikaroodi1, Matthew Denholtz1, Tom Lee1, Anil Bagri1, Lilly Wong1, Jode Goodridge1 and Bahram Valamehr1, 1Fate Therapeutics Inc., San Diego, CA, 2Fate Therapeutics Inc, San Diego, CA

    Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology